BIOMAT Database Logo BIOMAT Database Logo

In vitro and in vivo models of Pneumocystis carinii. 1997

M S Bartlett, and S F Queener, and M M Shaw, and P J Durant, and C H Lee, and J W Smith
Department of Pathology and Laboratory Medicine, Indiana University School of Medicine, Indianapolis, USA.

UI MeSH Term Description Entries
D007165 Immunosuppression Therapy Deliberate prevention or diminution of the host's immune response. It may be nonspecific as in the administration of immunosuppressive agents (drugs or radiation) or by lymphocyte depletion or may be specific as in desensitization or the simultaneous administration of antigen and immunosuppressive drugs. Antirejection Therapy,Immunosuppression,Immunosuppressive Therapy,Anti-Rejection Therapy,Therapy, Anti-Rejection,Therapy, Antirejection,Anti Rejection Therapy,Anti-Rejection Therapies,Antirejection Therapies,Immunosuppression Therapies,Immunosuppressions,Immunosuppressive Therapies,Therapies, Immunosuppression,Therapies, Immunosuppressive,Therapy, Immunosuppression,Therapy, Immunosuppressive
D008168 Lung Either of the pair of organs occupying the cavity of the thorax that effect the aeration of the blood. Lungs
D011010 Pneumocystis A genus of ascomycetous FUNGI, family Pneumocystidaceae, order Pneumocystidales. It includes various host-specific species causing PNEUMOCYSTIS PNEUMONIA in humans and other MAMMALS. Pneumocysti
D011020 Pneumonia, Pneumocystis A pulmonary disease in humans occurring in immunodeficient or malnourished patients or infants, characterized by DYSPNEA, tachypnea, and HYPOXEMIA. Pneumocystis pneumonia is a frequently seen opportunistic infection in AIDS. It is caused by the fungus PNEUMOCYSTIS JIROVECII. The disease is also found in other MAMMALS where it is caused by related species of Pneumocystis. P carinii Pneumonia,P. carinii Pneumonia,P. jirovecii Pneumonia,PCP Pneumonia,Pneumocystis Pneumonia,Pneumocystosis,Pneumonia, Interstitial Plasma Cell,PCP Infection,Pneumocystis carinii Pneumonia,Pneumocystis jirovecii Pneumonia,Pneumonia, Pneumocystis carinii,Infection, PCP,P carinii Pneumonias,P. carinii Pneumonias,P. jirovecii Pneumonias,PCP Infections,PCP Pneumonias,Pneumocystis Pneumonias,Pneumocystoses,Pneumonia, P carinii,Pneumonia, P. carinii,Pneumonia, P. jirovecii,Pneumonia, PCP,Pneumonia, Pneumocystis jirovecii,Pneumonias, PCP
D002460 Cell Line Established cell cultures that have the potential to propagate indefinitely. Cell Lines,Line, Cell,Lines, Cell
D004195 Disease Models, Animal Naturally-occurring or experimentally-induced animal diseases with pathological processes analogous to human diseases. Animal Disease Model,Animal Disease Models,Disease Model, Animal
D005347 Fibroblasts Connective tissue cells which secrete an extracellular matrix rich in collagen and other macromolecules. Fibroblast
D000818 Animals Unicellular or multicellular, heterotrophic organisms, that have sensation and the power of voluntary movement. Under the older five kingdom paradigm, Animalia was one of the kingdoms. Under the modern three domain model, Animalia represents one of the many groups in the domain EUKARYOTA. Animal,Metazoa,Animalia
D000935 Antifungal Agents Substances that destroy fungi by suppressing their ability to grow or reproduce. They differ from FUNGICIDES, INDUSTRIAL because they defend against fungi present in human or animal tissues. Anti-Fungal Agents,Antifungal Agent,Fungicides, Therapeutic,Antibiotics, Antifungal,Therapeutic Fungicides,Agent, Antifungal,Anti Fungal Agents,Antifungal Antibiotics
D051379 Mice The common name for the genus Mus. Mice, House,Mus,Mus musculus,Mice, Laboratory,Mouse,Mouse, House,Mouse, Laboratory,Mouse, Swiss,Mus domesticus,Mus musculus domesticus,Swiss Mice,House Mice,House Mouse,Laboratory Mice,Laboratory Mouse,Mice, Swiss,Swiss Mouse,domesticus, Mus musculus

Related Publications

M S Bartlett, and S F Queener, and M M Shaw, and P J Durant, and C H Lee, and J W Smith
In vitro and in vivo effects of quinupristin-dalfopristin against Pneumocystis carinii.
November 2001, Antimicrobial agents and chemotherapy,
M S Bartlett, and S F Queener, and M M Shaw, and P J Durant, and C H Lee, and J W Smith
In vitro and in vivo immunomodulatory effects of anti-Pneumocystis carinii drugs.
May 1996, Antimicrobial agents and chemotherapy,
M S Bartlett, and S F Queener, and M M Shaw, and P J Durant, and C H Lee, and J W Smith
In vitro studies of Pneumocystis carinii.
January 1989, The Journal of protozoology,
M S Bartlett, and S F Queener, and M M Shaw, and P J Durant, and C H Lee, and J W Smith
Propagation of Pneumocystis carinii in vitro.
April 1977, Pediatric research,
M S Bartlett, and S F Queener, and M M Shaw, and P J Durant, and C H Lee, and J W Smith
Animal models for Pneumocystis carinii pneumonia.
January 1989, The Journal of protozoology,
M S Bartlett, and S F Queener, and M M Shaw, and P J Durant, and C H Lee, and J W Smith
Overview of animal models of Pneumocystis carinii pneumonia.
January 1991, The Journal of protozoology,
M S Bartlett, and S F Queener, and M M Shaw, and P J Durant, and C H Lee, and J W Smith
Metabolic and synthetic activities of Pneumocystis carinii in vitro.
December 1981, Infection and immunity,
M S Bartlett, and S F Queener, and M M Shaw, and P J Durant, and C H Lee, and J W Smith
In vitro differentiation of human-derived Pneumocystis carinii.
March 1989, Journal of clinical microbiology,
M S Bartlett, and S F Queener, and M M Shaw, and P J Durant, and C H Lee, and J W Smith
In vitro activity of amprenavir against Pneumocystis carinii.
September 2001, International journal of antimicrobial agents,
M S Bartlett, and S F Queener, and M M Shaw, and P J Durant, and C H Lee, and J W Smith
Susceptibility of Pneumocystis carinii to artemisinin in vitro.
June 1991, Antimicrobial agents and chemotherapy,
Copied contents to your clipboard!